

## Dutch medicine shortage gets even worse

The Dutch medicine shortage increased by 51% last year. This worrisome development should warrant more attention from policymakers. Potential solutions, such as bringing notably generic medicine production back to Europe, are possible but costly



### Dutch medicine shortage continues to mount

We researched the European medicine shortage late last year and [predicted](#) that shortages will continue to rise for the foreseeable future. New data published this week on the Dutch medicine shortage confirmed our fears. Unfortunately, Dutch drug shortages increased by 51% in 2023 compared to 2022. In 2023, there were 2,292 instances where patients could not get the medicine they required, up from 1,514 in 2022.


Many European governments are currently reflecting on their dependencies in a changing world. These discussions on 'strategic autonomy' technology and many other things are actively being discussed. However, most (generic) medicine is produced overseas, mainly in India and China. With shortages continuing to rise and with ageing populations, medicines should be at the forefront of these discussions.

Solutions, like bringing, notably, generic medicine production back to Europe, are possible but costly. Yet, policymakers can ill afford to wait and need to make decisions, not least on

funding. Otherwise, medicine shortages in Europe will likely keep increasing.

## Dutch medicine shortage continues to mount

Number of instances in which a medicine was not available in Dutch pharmacies



Source: KNMP

We've written more extensively on Europe's medicine shortage and the potential solutions [here](#).

### Author

#### Diederik Stadig

Sector Economist, TMT & Healthcare

[diederik.stadig@ing.com](mailto:diederik.stadig@ing.com)

### Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. (“ING”) solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies)*. The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit <http://www.ing.com>.